Telix Pharmaceuticals Ltd (TLX) stock
Close on Nov 12, 2026Market cap $3.17BP/E –Yield –
Telix Pharmaceuticals Ltd grew revenue 55.6% to $803.79M over fiscal 2025. Operating income fell 46.0% to $29.78M, moving the operating margin from 10.7% to 3.7%. Free cash flow was -$42.99M, down 334.0% from a year earlier. At the latest close the market valued the company at $3.17B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.17B
- P/E ratio
- –
- Price to sales
- 3.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1.36%
Fundamentals
- Revenue
- $803.79M
- Net income
- -$7.13M
- EPS, diluted
- -$0.02
- Free cash flow
- -$42.99M
Trading
- Previous close
- $9.72
- Open
- $9.48
- Day's range
- $9.27 – $9.48
- Volume
- 251,937
- Average volume (20 days)
- 348,080
- Beta (5 years)
- 1.44
- 52-week range
- $6.28 – $13.11
- RSI (14 days)
- 43.0
- Volatility (1 year)
- 56.8%
- Relative volume
- 0.90×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TLX | S&P 500 | Difference | TLX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.1% | -2.7% | −14.4 pts | ||
| 3 months | -21.8% | -1.7% | −20.1 pts | ||
| Year to date | +25.0% | +11.9% | +13.1 pts | ||
| 1 year | -4.6% | +12.0% | −16.6 pts | ||
| 3 years | +3242.9% | +78.2% | +3164.7 pts | +222.1% | +21.2% |
| 5 years | +3242.9% | +73.2% | +3169.6 pts | +101.8% | +11.6% |
| 10 years | +3242.9% | +309.6% | +2933.2 pts | +42.0% | +15.1% |
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Telix Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Telix Pharmaceuticals
Pharmaceutical Preparations
Telix Pharmaceuticals is a biopharmaceutical enterprise focused on radiopharmaceuticals and molecularly targeted radiation technologies. The group conducts activities across three main operating segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its portfolio includes commercial diagnostics such as Illuccix (TLX591-CDx), alongside specialized diagnostic imaging candidates such as Zircaix, SENSEI, and Dedicaid QDOSE. The Therapeutics division focuses on clinical radiotherapeutic treatments, including TLX101-Tx, TLX591-Tx, TLX66-Tx, and TLX300-Tx. In addition, the Manufacturing Solutions segment delivers radiopharmacy operations, production capabilities, and technical supply chain services to healthcare providers, research collaborators, and commercial partners.
Company profile, executives and historyTelix Pharmaceuticals stock: common questions
What is Telix Pharmaceuticals's stock price?
TLX closed at $9.36 on Nov 12, 2026, down 3.75% on the day. Over the past 52 weeks it traded between $6.28 and $13.11.
What is Telix Pharmaceuticals's market cap?
Telix Pharmaceuticals was worth $3.17B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TLX's P/E ratio?
Telix Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.02), so it has no meaningful P/E ratio.
How much revenue does Telix Pharmaceuticals make?
Telix Pharmaceuticals reported revenue of $803.79M for fiscal 2025, up 55.6% from a year earlier.
Does Telix Pharmaceuticals pay a dividend?
No. Telix Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has TLX stock performed over the past year?
Including dividends, TLX returned -4.6% over the past year, against +12.0% for the S&P 500.
Who are Telix Pharmaceuticals's competitors?
Companies most similar to Telix Pharmaceuticals by business, industry and size include OPK, AAPG, RARE, EVO, HCM.
See a number that looks wrong?